Mathé G, Eriguchi M
Service des Maladies Sanguines, Immunitaires et Tumorales, ICIG, Hôpital Paul-Brousse, Villejuif, France.
Biomed Pharmacother. 1988;42(3):177-86.
Scientific criticism when analyzed in depth, appears to be as exacting as ethical criticism of statistics relating to adjuvant therapy comparative trial results, based on survival or on length of first remission. The heterogeneity of a population in which an exponential curve represents survival or period of disease-free survival (OFS) raises the issue of the significance of a benefit or absence of benefit provided by studied treatment. The segmentation of exponential curves into two or three slopes is proposed. This permits a more accurate evaluation of the results, as well as the application of several protocols, adapted to separate homogeneous groups of patients.
深入分析时，科学批评似乎与基于生存或首次缓解期长度的辅助治疗对比试验结果的统计学伦理批评一样严格。在一个指数曲线代表生存或无病生存期（OFS）的人群中，其异质性引发了所研究治疗带来的益处或无益处的意义问题。有人提出将指数曲线分为两三个斜率。这有助于更准确地评估结果，以及应用几种适用于不同同质患者群体的方案。
